REFERENCES

References

Aarts PA, Bolhuis PA, Sakariassen KS, Heethaar RM, Sixma JJ. Red blood cell size is important for adherence of blood platelets to artery subendothelium. Blood. 1983; 62:214-7.

Abendschein DR, Baum PK, Light DR, Morser J. Effect of vascular injury on inhibition of venous thrombosis with ZK-807834, a direct inhibitor of factor Xa. J Thromb Haemost. 2003; 1:1955-8.

Achison M, Elton CM, Hargreaves PG, Knight CG, Barnes MJ, Farndale RW. Integrin-independent tyrosine phosphorylation of p125 (fak) in human platelets stimulated by collagen. J Biol Chern. 2001; 276:3167-74.

Adiguzel E, Hou G, Mulholland D, Hopfer U, Fukai N, Olsen B, Bendeck M. Migration and growth are attenuated in vascular smooth muscle cells with type VIII collagen-null alleles. Arterioscler Thromb Vase Biol. 2006; 26:56-61.

Akkerhuis KM,. Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML. Fibrinogen Receptor Occupancy Study (FROST) Investigators. Safety and preliminary efficacy of one month glycoprotein lib/Ilia inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Eur Heart J 2000;21:2042-55.

Altman R, Scazziota AS, Herrera Mde L, Gonzalez C Thrombin generation by activated factor VII on platelet activated by different agonists. Extending the cell­based model of hemostasis. Thromb J 2006;4:5.

Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism. Nat Med. 2002; 8:247-52.

Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, Koller B, Phillips DR, Conley PB. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest. 2003;112:398-406.

Andrews RK, Suzuki-Inoue K, Shen Y, Tulasne D, Watson MC, Berndt MC. Interaction of calmodulin with the cytoplasmic domain of platelet glycoprotein VI. Blood. 2002; 99:4219-21.

Andrews RK, Gardiner EE, Shen Y, Whisstock JC, Berndt MC. Glycoprotein Ib­IX-V. Int J Biochem Cell Biol. 2003; 35: 1170-4.

Andrews RK, Gardiner EE, Shen Y, Berndt MC. Platelet interactions m thrombosis. IUBMB Life. 2004; 56:13-8.

119

References

Angelillo-Scherrer A, de Frutos P, Aparicio C, Melis E, Savi P, Lupu F, Arnout J, Dewerchin M, Hoylaerts M, Herbert J, Collen D, Dahlback B, Carrneliet P. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med. 2001; 7:215-21.

Angelillo-Scherrer A, Burnier L, Flores N, Savi P, DeMol M, Schaeffer P, Herbert JM, Lemke G, Goff SP, Matsushima GK, Earp HS, Vesin C, Hoylaerts MF, Plaisance S, Collen D, Conway EM, Wehrle-Haller B, Carrneliet P. Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy. J Clin Invest. 2005; 115:237-46.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Escaned J, Moreno R, Hernandez-Antolin R, Sabate M, Trabetti E, Pignatti PF, Macaya C. 807 CIT Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagul Fibrinolysis. 2004; 15: 427-33.

Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.

Anti M, von Bruhl ML, Eiglsperger C, Werner M, Konrad I, Kocher T, Wilm M, Hofmann F, Massberg S, Schlossmann J. IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation. Blood. 2007; 109:552-9.

Apitz-Castro R, Badimon JJ, Badimon L. Effect of ajoene, the major antiplatelet compound from garlic, on platelet thrombus formation. Thromb Res. 1992; 68:145-55.

Apitz-Castro R, Badimon JJ, Badimon L. A garlic derivative, ajoene, inhibits platelet deposition on severely damaged vessel wall in an in vivo porCine experimental model. Thromb Res.I994; 75:243-9.

Argiolas L, Fabi F, del Basso P. Mechanisms of pulmonary vasoconstriction and bronchoconstriction produced by P AF in the guinea-pig: role of platelets and cyclo-oxygenase metabolites. Br J Pharmacal. 1995; 114:203-9.

Armstrong RA. Platelet prostanoid receptors. Pharmacal Ther. 1996;72:171-91.

Asano M, Branemark P-I, Castenholz A. A comparative study of continuous qualitative and quantitative analysis of microcirculation in man: microchymography and microphotoelectric plethysmography applied to microvascular investigation. Adv Microcirc. 1973; 5: 1-31.

Aukrust P, Muller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Froland SS, Gullestad L. Enhanced levels of soluble and membrane­bound CD40 ligand in patients with unstable angina. Possible reflection of T

120

References

lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999; 100:614-20.

Bagge U, Skalak R, Attefors R. Granulocyte rheology: experimental studies in an in-vitro micro-flow system. Adv Microcirc. 1977; 7:29-49.

Bahra P, Nash GB. Sparsely adherent platelets support capture and immobilization of flowing neutrophils. J Lab Clin Me d. 1998; 132:223-8.

Barnes CS, Krafft B, Frech M, Hofmann UR, Papendieck A, Dahlems U, Gellissen G, Hoylaerts MF. Production and characterization of saratin, an inhibitor of von Wille brand factor-dependent platelet adhesion to collagen. Semin Thromb Hemost. 2001;27:337-48.

Basani RB, D'Andrea G, Mitra N, Vilaire G, Richberg M, Kowalska MA, Bennett JS, Poncz M. ROD-containing peptides inhibit fibrinogen binding to platelet alpha(Ilb )beta3 by inducing an allosteric change in the amino-terminal portion of alpha(Ilb). J Bioi Chern. 2001;276:13975-81.

Batra S, Roy AK, Patra A, Bhaduri AP, Surin WR, Raghavan SA, Sharma P, Kapoor K, Dikshit M. Baylis-Hillman reaction assisted parallel synthesis of 3,5-disubstituted isoxazoles and their in vivo bioevaluation as antithrombotic agents. Bioorg Med Chern. 2004; 12:2059-77.

Baumgartner HR, Muggli R. Adhesion and aggregation: Morphological demonstration and quantification in vivo and in vitro, in Gordon JL ( ed): Platelets in Biology and Pathology. New York, NY, Elsevier/North-Holland, 1976, p 23

Baumgartner HR. Platelet interaction with collagen fibrils in flowing blood. I. Reaction of human platelets with alpha chymotrypsin-digested subendothelium. Thromb Haemost. 1977; 37:1-16.

Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacal. 2003; 25:831-55.

Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287:2570-81.

Begonja AJ, Gambaryan S, Geiger J, Aktas B, Pozgajova M, Nieswandt B, Walter U. Platelet NAD(P)H-oxidase-generated ROS production regulates alphaiibbeta3-integrin activation independent of the NO/cGMP pathway. Blood. 2005; 106:2757-60.

Bergmeier W, Bouvard D, Eble JA, Mokhtari-Nejad R, Schulte V, Zirngibl H, Brakebusch C, Fassler R, Nieswandt B. Rhodocytin (aggretin) activates platelets lacking a2P1 integrin, glycoprotein VI, and the ligand-binding domain of glycoprotein lba. J Bioi Chern. 2001; 276:25121-6.

121

References

Bergqvist D. Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery. Br J Surg. 2004; 91:965-74.

Bergqvist D. Venous thromboembolism: a review of risk and prevention m colorectal surgery patients. Dis Colon Rectum. 2006; 49:1620-8.

Bernardi B, Guidetti GF, Campus F, Crittenden JR, Graybiel AM, Balduini C, Torti M. The small GTPase Rap1b regulates the cross talk between platelet integrin alpha2beta1 and integrin alphallbbeta3. Blood. 2006; 107:2728-35.

Best CH. Preparation of heparin and its use in the first clinical cases. Circulation. 1959; 19:79-86.

Bigalke B, Lindemann S, Ehlers R, Seizer P, Daub K, Langer H, Schonberger T, Kremmer E, Siegel-Axel D, May AE, Gawaz M. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006; 27:2165-9.

Blann AD, Naqvi T, Waite M, McCollum CN. von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens. 1993; 7:107-111.

Blobe GC, Stribling S, Obeid LM, Hannun Y A. Protein kinase C isoenzymes: regulation and function. Cancer Surv. 1996; 27:213-48.

Blockmans D, Deckmyn H, Vermylen J. Platelet activation. Blood Rev. 1995; 9:143-56.

Blum A. White blood cell count and the coronary anatomy in acute coronary events. Am J Cardia!. 2005; 95:159-60.

Bori-Sanz T, Inoue KS, Berndt MC, Watson SP, Tulasne D. Delineation of the region in the glycoprotein VI tail required for association with the Fe receptor gamma-chain. J Biol Chern. 2003; 278:35914-22.

Boulanger CM. Secondary endothelial dysfunction: hypertension and heart failure. J Mol Cell Cardia!. 1999; 31:39-49.

Brass LF. Thrombin and platelet activation. Chest. 2003;124:18S-25S.

Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH. Cloned and expressed "nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature. 1991; 351:714-8.

Briddon SJ, Melford SK, Turner M, Tybulewicz V, Watson SP. Collagen mediates changes in intracellular calcium in primary mouse megakaryocytes through syk-dependent and -independent pathways. Blood. 1999; 93:3847-55.

122

References

Bugaud F, Nadal-Wollbold F, Levy-Toledano S, Rosa JP, Bryckaert M. Regulation of c-jun-NH2 terminal kinase and extracellular-signal regulated kinase in human platelets. Blood. 1999; 94:3800-5.

Cadroy Y, Hanson SR. Effects of red blood cell concentration on hemostasis and thrombus formation in a primate model. Blood. 1990; 75:2185-93.

Calverley DC, Hacker MR, Loda KA, Brass E, Buchanan TA, Tsao-Wei DD, Groshen S. Increased platelet Fe receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus. Br J Haematol. 2003;121: 139-42.

Calvete JJ. On the structure and function of platelet integrin alpha lib beta 3, the fibrinogen receptor. Proc Soc Exp Bioi Med. 1995; 208: 346-60.

Canobbio I, Balduini C, Torti M. Signalling through the platelet glycoprotein Ib­V-IX complex. Cell Signal. 2004; 16:1329-44.

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348: 1329-39.

Carlson SA, Chatterjee TK, Murphy KP, Fisher RA. Mutation of a putative amphipathic alpha-helix in the third intracellular domain of the platelet-activating factor receptor disrupts receptor/G protein coupling and signaling. Mol Pharmacal. 1998; 53:451-8.

Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The a 2 gene coding sequence T807 I A873 of the platelet collagen receptor integrin a 2p 1 might be a genetic risk factor for the development of stroke in younger patients. Blood. 1999; 93:3583-6.

Casserly IP, Topol EJ. Glycoprotein lib/Ilia antagonists--from bench to practice. Cell Mol Life Sci. 2002; 59:4 78-500.

Cattaneo M. P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents. Eur Heart J 2006; 27: 1010-2.

Cauwenberghs N, Vanhoorelbeke K, Vauterin S, Westra DF, Romo G, Huizinga EG, Lopez JA, Berndt MC, Harsfalvi J, Deckmyn H. Epitope mapping of inhibitory antibodies against platelet glycoprotein Iba reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood. 2001; 98:652-60.

Cesar JM, Garcia-Avello A, Navarro JL, Herraez MV. Aging and oral anticoagulant therapy usmg acenocoumarol. Blood Coagul Fibrinolysis. 2004; 15:673-6.

123

References

Chen H, Locke D, Liu Y, Liu C, Kahn ML. The Platelet Receptor GPVI Mediates Both Adhesion and Signaling Responses to Collagen in a Receptor Density­dependent Fashion. J Bioi Chem. 2002; 277: 3011-9.

Chen H, Kahn ML. Reciprocal signaling by integrin and nonintegrin receptors during collagen activation of platelets. Mol Cell Bioi. 2003; 23:4764-77.

Chen C, Li Q, Darrow AL, Wang Y, Derian CK, Yang J, de Garavilla L, Andrade-Gordon P, Damiano BP. Mer receptor tyrosine kinase signaling participates in platelet function. Arterioscler Thromb Vase Bioi. 2004; 24:1118-23.

Chiang TM. Development of peptide inhibitors to block type I and type III collagen-platelet interaction. Curr Med Chem Cardiovase Hematol Agents. 2003; 1:171-5.

Cho J, Mosher DF. Role offibronectin assembly in platelet thrombus formation. J Thromb Haemost. 2006; 4:1461-9.

Choi W, Karim ZA, Whiteheart SW. Arf6 plays an early role in platelet activation by collagen and convulxin. Blood. 2006; 107:3145-52. ·

Chong BH. Heparin-induced thrombocytopenia. Aust N Z J Med. 1992; 22:145-52.

Chu X, Hou M, Peng J, Zhu Y, Zhang F, Ji X, Wang L, Ma D. Identification of human platelet glycoprotein VI-specific IgG autoantibody and its fragments. Blood Coagul Fibrinolysis. 2006; 17:403-7.

Chung CH, Peng HC, Huang TF. Aggretin, a C-type lectin protein, induces platelet aggregation via integrin a2~ 1 and GPib in a phosphatidylinositol 3-kinase independent pathway. Bioehem Biophys Res Commun. 2001; 285:689-95.

Clark EA, Shattil SJ, Ginsberg MH, Bolen J, Brugge JS. Regulation of the protein tyrosine kinase pp72syk by platelet agonists and the integrin alpha lib beta 3. J Bioi Chem. 1994; 269:28859-64.

Clauser S, Bachelot-Lozat C, Fontana P, Gaussem P, Remones V, Aiach M, Borgel D. Physiological plasma Gas6 levels do not influence platelet aggregation. Arterioscler Thromb Vase Bioi. 2006; 26:e22.

Clements JL, Lee JR, Gross B, Yang B, Olson JD, Sandra A, Watson SP, Lentz SR, Koretzky GA. Fetal hemorrhage and platelet dysfunction in SLP-76-deficient mice. JC!inlnvest. 1999; 103:19-25.

Coller BS, Beer JH, Scudder LE, Steinberg MH. Collagen-platelet interactions: evidence for a direct interaction of collagen with platelet GPia/IIa and an indirect

124

References

interaction with platelet GPIIb/IIIa mediated by adhesive proteins. Blood. 1989; 74:182-189.

Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003; 26:2181-8.

Crabos M, Imber R, Woodtli T, Fabbro D, Erne P. Different translocation of three distinct PKC isoforms with tumor-promoting phorbol ester in human platelets. Biochem Biophys Res Commun. 1991; 178: 878-83.

Davies MJ. Pathology of arterial thrombosis. Br Med Bull. 1994; 50:789-802.

DeClerck F, Beetens J, De Chaffoy De Courcelles D, Freyne E, Janssen PAJ. R6 8070: Thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade in one molecule-!. Thromb Haemost. 1989a; 61:35-42.

DeClerck F, Beetens J. Van De Water A, Vercammen E, Janssen PAJ. R68070: Thromboxane A2/prostaglandinendoperoxide receptor blockade in one molecule­II. Pharmacological effect in vitro and ex-vivo. Thromb Haemost 1989b; 61:43-9.

De Marco L, Mazzucato M, Masotti A, Fenton JW 2nd, Ruggeri ZM. Function of glycoprotein Ib alpha in platelet activation induced by alpha-thrombin. J Biol Chern. 1991; 266:23776-83.

De Meyer SF, Vanhoorelbeke K, Ulrichts H, Staelens S, Feys HB, Salles I, Fontayne A, Deckmyn H. Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs. Cardiovasc Hematol Disord Drug Targets. 2006; 6:191-207.

Deckmyn H, Stassen JM, Vreys I, Van Houtte E, Sawyer RT, Vermylen J. Calin from Hirudo medicinalis, an inhibitor of platelet adhesion to collagen, prevents platelet rich thrombosis in hamsters. Blood. 1995; 85; 712-9.

Deckmyn H, Cauwenberghs N, Wu D, Depraetere H, Vanhoorelbeke K. Development of antibodies that interfere with the collagen-VWF-GPib axis as new antithrombotics. Verh K Acad Geneeskd Belg. 2005; 67:55-65.

Dejana E, Callioni A, Quintana A, Gaetano G. Bleeding time in laboratory animals. II - A comparison of different assay conditions in rats. Thromb Res. 1979; 15:191-7.

Dikshit M, Kumari R, Srimal RC. Pulmonary thromboembolism-induced alterations in nitric oxide release from rat circulating neutrophils. J Pharmacal Exp Ther. 1993; 265:1369-73.

125

References

DiMinno G, Silver MJ. Mouse antithrombotic assay: a simple method for the evaluation of antithrombotic agents in vivo. Potentiation of antithrombotic activity by ethyl alcohol. J Pharmacal Exp Ther. 1983: 225:57-60.

Dodson PM, Haynes J, Starczynski J, Farmer J, Shigdar S, Fegan G, Johnson RJ, Fegan C. The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion. Eye. 2003; 17: 772-7.

Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS; Cilostazol for Restenosis Trial (CREST) Investig'ators. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005; 112:2826-32.

D'Souza SE, Ginsberg MH, Matsueda GR, Plow EF. A discrete sequence in a platelet integrinis involved in ligand recognition. Nature. 1991; 350: 66-8.

Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie BC. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood 2006; 107: 3902-6.

Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch JS, Imai M, Edelberg JM, Rayburn H, Lech M, Beeler DL, Csizmadia E, Wagner DD, Robson SC, Rosenberg RD. Targeted disruption of cd39/ ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Me d. 1999; 5:101 0-7.

Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin­catalyzed activation of protein C. Proc Natl Acad Sci US A. 1981; 78:2249-52.

Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem. 1982; 257:7944-7.

ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006;367:1665-73.

Essler M, Retzer M, Bauer M, Zangi KJ, Tigyi G, Siess W. Stimulation of platelets and edothelial cells by mildly oxidized low density lipoprotein proceeds through activation of lysophophatidic acid receptors and the Rho/Rho-kinase pathway. Inhibition by lovastatin. Ann NY Acad Sci. 2000; 905:282-86.

Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, Koller BH. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med. 1999; 5: 1199-202.

126

References

Fadl YY, Zareba W, Moss AJ, Marder VJ, Sparks CS, Miller Watelet LF, Carroll ER. History ofl:;typertension and enhanced thrombogenic activity in postinfarction patients. Hypertension. 2003;41 :943-9.

Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33:523-30.

Falet H, Rendu F. Calcium mobilisation controls tyrosine protein phosphorylation independently of the activation of protein kinase C in human platelets. FEES Lett. 1994; 345:87-91.

Farndale RW, Sixma JJ, Barnes MJ, de Groot PO. The role of collagen in thrombosis and hemostasis. J Thromb Haemost. 2004; 2: 561-73.

Feher MD. Diabetes: preventing coronary heart disease in a high risk group. Heart. 2004; 90:18-21.

Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. CyclicGMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res. 2003; 93:907-16.

Feinstein MB, Fraser C. Human platelet secretion and aggregation induced by calcium ionophores. Inhibition by PGE1 and dibutyryl cyclic AMP. J Gen Physiol. 1975; 66: 561-81.

Feldstein CA. Sibrafiban (Genentech). !Drugs. 1999;2:460-5.

Ferguson JJ, Kereiakes DJ, Adgey AA, Fox KA, Hillegass WB Jr, Pfisterer M, Vassanelli C. Safe use of platelet GP lib/lila inhibitors. Am Heart J 1998;135:S77-89.

Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundstrom T, Berkowitz SD, Nystrom P, Thorsen M, Ginsberg JS. THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005; 293:681-9.

FitzGerald GA, Healy C, Daugherty J. Thromboxane A2 biosynthesis in human disease. Fed Proc. 1987; 46:154-8.

Flaumenhaft R, Sim DS. The platelet as a model for chemical genetics. Chern Bioi. 2003; 10: 481-6.

Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ Jr, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS. Molecular identification and characterization of the

127

References

platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001; 107: 1591-8.

Francischetti IM, Saliou B, Leduc M, Carlini CR, Hatmi M, Randon J, Faili A, Bon C. Convulxin, a potent platelet-aggregating protein froni Crotalus durissus terrificus venom, specifically binds to platelets. Toxicon. 1997; 35:1217-28.

Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997; 100:350-6.

Friedel HA, Balfour JA. Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs. 1994;48:638-60.

Frishman WH, Bums B, Atac B, Alturk N, Altajar B, Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein lib/Ilia integrin receptor. Am Heart J 1995; 130:877-92.

Fung CY, Brearley CA, Famdale RW, Mahaut-Smith MP. A major role for P2X1

receptors in the early collagen-evoked intracellular Ca2+ responses of human

platelets. Thromb Haemost. 2005; 94:37-40.

Furie B. Mutations in protein C: molecular pathology ofthrombosis. J Lab Clin Med. 1992; 119:592-3.

Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest. 2005;115:3355-62.

Furie BC, Furie B. Tissue factor pathway vs. collagen pathway for in vivo platelet activation. Blood Cells Mol Dis. 2006; 36:135-8.

Furuya A, KatoN, Jingu S, Akimoto M, Kasai 0, Suwa T, Sato M, Ogata H. Comparison of stepwise and simultaneous estimations of population pharmacokinetics and pharmacodynamics of TS-943. Eur · J Drug Metab Pharmacokinet. 2003; 28:191-9.

Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Eng! J Med. 1992; 326:310-8.

Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost. 2001; 86:222-32.

Gachet C, Hechler B. The platelet P2 receptors in thrombosis. Semin Thromb He most. 2005; 31: 162-7.

128

References

Gailani D, Broze GJ Jr. Factor XU-independent activation of factor XI in plasma: effects ofsulfatides on tissue factor-induced coagulation. Blood 1993;82:813-9.

Gao J, Zoller KE, Ginsberg MH, Brugge JS, Shattil SJ. Regulation of the pp72syk protein tyrosine kinase by platelet integrin alpha Ilb beta 3. EMBO J 1997; 16:6414-25.

Gaussem P, Dubar M, le Bonniec B, Richard-Lordereau I, Jochemsen R, Aiach M. Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects. Br J Clin Pharmacal. 2002;53: 14 7-54.

Gawaz M, Neumann FJ, Dickfeld T, Reininger A, Adelsberger H, Gebhardt A, Schomig A. Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation. 1997;96: 1809-18.

Gear AR, Simon CG, Polanowska-Grabowska R. Platelet adhesion to collagen activates a phosphoprotein complex of heat-shock proteins and protein phosphatase!. J Neural Transm. 1997; 104:1037-47.

Gerrard JM, White JG, Rao GH, Townsend D. Localization of platelet prostaglandin production in the platelet dense tubular system. Am J Pathol. 1976; 83:283-98.

Ghuysen A, Dogne JM, Chiap P, Rolin S, Masereel B, Lambermont B, Kolh P, Tchana-Sato V, Hanson J, D'Orio V. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor. Cardiovasc Drug Rev. 2005; 23:1-14.

Gibbins J, Asselin J, Farndale R, Barnes MJ, Law CL, Watson SP. Tyrosine phosphorylation of the Fe receptor c-chain in collagen stimulated platelets. J Biol Chem. 1996; 271: 18095-9.

Gibbins JM, Briddon S, Shutes A, van Vugt MJ, van de Winkel JG, Saito T, Watson SP. The p85 subunit of phosphatidylinositol 3-kinase associates with the Fe receptor y-chain and linker for activator of T cells (LAT) in platelets stimulated by collagen and convulxin. J Bioi Chem. 1998; 273: 34437-43.

Gleerup G, Winther K. Decreased fibrinolytic activity and increased platelet function in hypertension: possible influence of calcium antagonism. Am J Hypertens. 1991; 4:168S-171S.

Golino P, Ragni M,. Cirillo P, Pascucci I, Ezekowitz MD, Pawashe A, Scognamiglio A, Pace L, Guarino A, Chiariello M. Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid

129

References

arteries more effectively than other antiplatelet interventions. Thromb Haemost. 1995; 74:974-9.

Goncalves I, Hughan SC, Schoenwaelder SM, Yap CL, Yuan Y, Jackson SP. Integrin alpha lib beta 3-dependent calcium signals regulate platelet-fibrinogen interactions under flow. Involvement of phospholipase C gamma 2. J Bioi Chern. 2003 ;278 :34812-22.

Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005; 6:3-11.

Gould WR, Baxi SM, Schroeder R, Peng YW, Leadley RJ, Peterson JT, Perrin LA. Gas6 receptors Axl, Sky and Mer enhance platelet activation and. regulate thrombotic responses. J Thromb Haemost. 2005; 3:733-41.

Grabarek J, Raychowdhury M, Ravid K, Kent KC, Newman PJ, Ware JA. Identification and functional characterization of protein kinase C isozymes in platelets and HEL cells. J Bioi Chem. 1992; 267:10011-7.

Green D. Coagulation cascade. Hemodial Int. 2006; 10:S2-4.

Gross BS, Lee JR, Clements JL, Turner M, Tybulewicz VL, Findell PR, Koretzky GA, Watson SP. Tyrosine phosphorylation of SLP-76 is downstream of Syk following stimulation of the collagen receptor in platelets. J Bioi Chem. 1999; 274: 5963-71. .

Guest MM. Profibrinolysin, antifibrinolysin, fibrinogen and urine fribrinolytic factors in the human subject. J Clin Invest. 1954; 33:1533-59.

Guth BD, Muller TH. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. Basic Res Cardia!. 1997; 92:181-90.

Hamberg M, Svensson J, Samuelsson B. Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proc Nat! Acad Sci US A. 1974; 71 :3824-8.

Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Nat! Acad Sci US A. 1975; 72:2994-8.

Hamby L, Weeks WB, Malikowski C. Complications ofwarfarin therapy: causes, costs, and the role of the anticoagulation clinic. Eff Clin Pract. 2000;3: 179-84.

Hamilton SF, Miller MW, Thompson CA, Dale GL. Glycoprotein lib/Ilia inhibitors increase COAT-platelet production in vitro. J Lab Clin Med 2004; 143:320-6.

130

References

Hanson J, Rolin S, Reynaud D, Qiao N, Kelley LP, Reid HM, Valentin F, Tippins J, Kinsella BT, Masereel B, Pace-Asciak C, Pirotte B, Dogne JM. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'­methylphenylamino )-5-nitrobenzenesulfonyl]urea ], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist. J Pharmacal Exp Ther. 2005; 313:293-301.

Harlan JM, Killen PD, Harker LA, Striker GE, Wright DG. Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment. J Clin Invest. 1981; 68:1394-403.

Harrington RA, Armstrong PW, Graffagnino C, Van De Werf F, Kereiakes DJ, Sigmon KN, Card T, Joseph DM, Samuels R, Granett J, Chan R, Califf RM, Topol EJ. Dose-finding, safety, and tolerability study of an oral platelet glycoprotein lib/Ilia inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. Circulation. 2000; 102 :728-35.

Hayashi M, Matsuo A, Nakamoto H, Aisaka K. Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV -803, in animals. Eur J Pharmacal. 2001; 412:61-6.

Hechler B, Lenain N, Marchese P, Vial C, Heim V, Freund M, Cazenave JP, Cattaneo M, Ruggeri ZM, Evans R, Gachet C. A role of the fast ATP-gated P2X1

cation channel in thrombosis of small arteries in vivo. J Exp Med. 2003;198:661-7.

Hemker HC, ·Giesen PL, Ramjee M, Wagenvoord R, Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost. 2000; 83:589-91.

Hemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test ofthe haemostatic-thrombotic system. Thromb Haemost. 2006; 96:553-61.

Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391 :591-4.

Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001; 98:1047-54.

Hirsch E, Bosco 0, Tropel P, Laffargue M, Calvez R, Altruda F, Wymann M, Montrucchio G. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J. 2001; 15:2019-21.

Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001; 119:8S-21 S.

131

References

Hirsh J. Advances and contemporary issues in prophylaxis for deep vein thrombosis. Chest. 2003;124:347S-48S.

Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman­Cullere M, Ross FP, Coller BS, Teitelbaum S, Hynes RO. Beta3-integrin­deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999; 103:229-38.

Hoffman M, Blum A, Baruch R, Kaplan E, Benjamin M. Leukocytes and coronary heart disease. Atherosclerosis. 2004; 172:1-6.

Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001; 409:202-7.

Hong TT, Huang J, Driscoll E, Lucchesi BR. Preclinical evaluation of S 18886 in an experimental model of coronary arterial thrombosis. J Cardiovasc Pharmacal. 2006;48:239-48 ..

Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost. 2004; 2:2138-45.

Hubbard GP, Wolffram S, de Vos R, Bovy A, Gibbins JM, Lovegrove JA Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: a pilot study. Br J Nutr. 2006; 96:482-8.

HugH, Sarre TF. Protein kinase C isoenzymes: divergence in signal transduction? Biochem J 1993; 291:329-43.

Ignarro LJ. Nitric oxide-mediated vasorelaxation. Thromb Haemost. 1993; 70:148-51.

Inoue 0, Suzuki-Inoue K, Dean WL, Frampton J, Watson SP. Integrin alpha2betal mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2. J Cell Biol. 2003; 160:769-80.

Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutivelyexpressed on platelets and provides a novel mechanism for platelet activation. Circ Res. 2003; 92:1041-8.

Ishimoto Y, Nakano T. Release of a product of growth arrest-specific gene 6 from rat platelets. FEES Lett. 2000; 466:197-9.

Ishimura M, Kataoka S, Suda M, Maeda T, Hiyama Y. Effects ofKP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions

132

References

induced by various agonists in the guinea pig trachea. Allergollnt. 2006; 55:403-10.

Jandrot-Perrus M, Lagrue AH, Okuma M, Bon C. Adhesion and activation of human platelets induced by convulxin involve glycoprotein VI and integrin a2p1•

J Bioi Chern. 1997; 272: 27035-41.

Judd BA, Myung PS, Leng L, Obergfell A, Pear WS, Shattil SJ, Koretzky GA. Hematopoietic reconstitution of SLP-76 corrects hemostasis and platelet signaling through alpha Ilb beta 3 and collagen receptors. Proc Nat! Acad Sci US A. 2000; 97:12056-61.

Jung SM, Moroi M. Activation of the platelet collagen receptor integrin alpha (2) beta (1 ): its mechanism and participation in the physiological functions of platelets. Trends Cardiovasc Med. 2000a; 10:285-92.

lung SM, Moroi M. Signal-transducing mechanisms involved in activation of the platelet collagen receptor integrin alpha (2) beta (1 ). J Bioi Chem. 2000b; 275:8016-26.

Jung SM, Ohnuma M, Watanabe N, Sonoda M, Handa M, Moroi M. Analyzing the mechanism of Rap1 activation in platelets: Rapl activation is related to the release reaction mediated through the collagen receptor GPVI. Thromb Res. 2006; 118: 509-21.

Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease­activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999; 103:879-87.

Kammerer B, Kahlich R, Ufer M, Laufer S, Gleiter CH. Determination of (R)­and (S)-phenprocoumon in human plasma by enantioselective liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom. 2004; 18:458-:64.

Kannel WB, Dawber TR, Sorlie P, Wolf P A. Components of blood pressure and risk of atherothrombotic brain infarction: the Framingham study. Stroke. 1976;7:327-31.

Kato K, Kanaji T, Russell S, Kunicki TJ, Furihata K, Kanaji S, Marchese P, Reininger A, Ruggeri ZM, Ware J. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood. 2003; 102:1701-7.

Kawano KI, Fujishima K, Ikeda Y, Kondo K, Umemura K. ME3277, a GPIIb/Illa antagonist reduces cerebral infarction without enhancing intracranial hemorrh~ge in photothrombotic occlusion of rabbit middle cerebral artery. J Cereb Blood Flow Metab. 2000;20 :988-97.

133

References

Kearney D, Byrne A, Crean P, Cox D, Fitzgerald DJ. Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective· cyclooxygenase-2 inhibitor. JAm Coil Cardiol. 2004; 43:526-31.

Keenan CR, White RH. Age as a risk factor for venous thromboembolism after major surgery. Curr Opin Pulm Med. 2005; 11:398-402.

Kehrel B, Balleisen L, Kokott R, Mesters R, Stenzinger W, Clemetson KJ, van de Loo J. Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood.1988; 71: 1074-8.

Kelton JG, Sheridan D, Santos A, Smith J, Steeves K, Smith C, Brown C, Murphy WG. Heparin-induced thrombocytopenia: laboratory studies. Blood. 1988; 72:925-30.

Keller PM, Schultz LD, Condra C, Karczewski J, Connolly TM. An inhibitor of collagen-stimulated platelet activation from the salivary glands of the Haementeria officinalis leech. II. Cloning o fthe eDNA and expression. J Bioi Chern. 1992; 267: 6899-904.

Keuren JF, Wielders SJ, Ulrichts H, Hackeng T, Heemskerk JW, Deckmyn H, Bevers EM, Lindhout T. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-!. Arterioscler Thromb Vase Bioi. 2005; 25:1499-505.

Kini AS, Richard M, Suleman J, Perez N, Lee P, Fisher EA, Kamran M, Marmur JD, Sharma SK. Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). Am J Cardia!. 2002; 90:526-9.

Kondo N, Wakayama F, Suzuki Y, Fukui K, Takaya S, Fukuda I. The state of platelets preserved in extracorporeal circulation with a glycoprotein lib/Ilia inhibitor. Thromb Res. 2004;113:303-10.

Konishi H, Katoh Y, Takaya N, Kashiwakura Y, Itoh S, Ra C, Daida H. Platelets Activated by Collagen Through Immunoreceptor Tyrosine-Based Activation Motif Play Pivotal Role in Initiation and Generation of Neointimal Hyperplasia After Vascular Injury. Circulation. 2002; 105:912-6.

Kunicki TJ, Orchekowski R, Annis D, Honda Y. Variability of integrin a2~ 1 activity on human platelets.Blaad.1993; 82: 2693-703.

Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin a2~1 density is associated with two silent polymorphisms in the a 2 gene coding sequence. Blood.l997; 89: 1939-43.

134

References

Kunicki TJ, Nugent DJ. The influence of platelet glycoprotein polymorphisms on receptor function and risk for thrombosis. Vox Sang. 2002; 83:85-90.

Kunicki TJ. The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vase Bioi. 2002;22 :14-20.

Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res. 1990; 60:269-80.

Laman JD, De Boer M, Hart BA. CD40 in clinical inflammation: from multiple sclerosis to atherosclerosis. Dev Immunol. 1998; 6:215-22.

Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies 0. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid­induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995;83 :483-92.

Lapchak P A, Araujo DM. Therapeutic Potential of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in the Management of Ischemic Stroke. Am J Cardiovasc Drugs. 2003; 3:87-94.

Laposata M, Krueger CM, Saffitz JE. Selective Uptake of [3H1Arachidonic Acid Into the Dense Tubular System of Human Platelets. Blood. 1987; 70: 832-37.

Larson MK, Chen H, Kahn ML, Taylor AM, Fabre JE, Mortensen RM, Conley PB, Parise LV. Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap 1 activation in platelets. Blood. 2003; 101:1409-15.

Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. A phase II randomised, double-blind, five-arm, parallel group, dose- response study of a new oral directly-acting factor-Xa inhibitor, Razaxaban, for prevention of deep vein thrombosis in knee-replacement surgery-on behalf of the Razaxaban Investigators [abstract]. Blood. 2003;102:11 [Suppl abstract 41].

Lasser G, Guchhait P, Ellsworth JL, Sheppard P, Lewis K, Bishop P, Cruz MA, Lopez JA, Fruebis J. C1qTNF-related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen. Blood. 2006; 107:423-30.

Law DA, Nannizzi-Alaimo L, Phillips DR. Outside-in integrin signal transduction. Alpha lib beta 3-(GP lib Ilia) tyrosine phosphorylation induced by platelet aggregation. J Bioi Chem. 1996; 271:10811-5.

Law DA, Nannizzi-Alaimo L, Ministri K, Hughes PE, Forsyth J, Turner M, Shattil SJ, Ginsberg MH, Tybulewicz VL, Phillips DR. Genetic and

135

References

pharmacological analyses of Syk function in alphallbbeta3 signaling in platelets. Blood. 1999;93 :2645-52.

Lawson EC, Hoekstra W J, Addo MF, Andrade-Gordon P, Damiano BP, Kauffman JA, Mitchell JA, Maryanoff BE. 1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/llla) antagonists. Bioorg Med Chern Lett. 2001; 11:2619-22.

Leadley RJ Jr, Chi L, Rebello SS, Gagnon A. Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents. J Pharmacal Toxicol Methods. 2000; 43:101-16.

Lecut C, Feijge MA, Cosemans JM, Jandrot-Perrus M, Heemskerk JW. Fibrillar type I collagens enhance platelet-dependent thrombin generation via glycoprotein VI with direct support of alpha2beta1 but not alpha1Ibbeta3 integrin. Thromb Haemost. 2005; 94:107-14.

Leng XH, Zhang W, Nieswandt B, Bray PF. Effects of estrogen replacement therapies on mouse platelet function and glycoprotein VI levels. Circ Res. 2005;. 97:415-7.

Leon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave }P, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(l) receptor-null niice. J Clin Invest. 1999; 104:1731-7.

Libby P, Mach F, Schonbeck U, Bourcier T, Aikawa M. Regulation of the thrombotic potential of atheroma. Thromb Haemost. 1999; 82:736-41.

Lichtman MA. Rheology of leukocytes, leukocyte suspensions and blood m leukemia. J Clin Invest. 1973; 52:350-8.

Liesenfeld KH, Schafer HG, Troc6niz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacal. 2006; 62:527-37.

Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ. Sustained suppression of ischemic complications of coronary intervention by platelet GP lib/lila blockade with abciximab: one-year outcome in the EPILOG trial.Evaluation in PTCA to Improve Long-term Outcome with abciximab GP lib/Ilia blockade. Circulation. 1999; 99:1951-8.

Linder MW. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant Warfarin. Clin Chim Acta. 2001; 308:9-15.

136

References

Lip GYH, Blann AD. Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation. 2000; 101 :218-20.

Liu CZ, Wu TF, Huang TF, Wu DH, Lin GL. Trimucytin, a collagen-like snake· venom protein, activates platelets independent of !-domain within a2 subunit of a 2P1 integrin. Thromb Res. 2002; 105:153-60.

Liu J, Pestina TI, Berndt MC, Steward SA, Jackson CW, Gartner TK. The roles of ADP and TXA2 in botrocetinNWF-induced aggregation of washed platelets. J Thromb Haemost. 2004; 2: 2213-22.

Liu CZ, Wang YC, Wang JH, Shaw CK, Lin GL. Differential expression of platelet glycoprotein Ia!IIa in Taiwan Chinese corresponds to glycoprotein ia gene polymorphisms. J Pharmacal Sci. 2006; 101:103-6.

LockeD, Liu C, Peng X, Chen H, Kahn ML. Fe Ry in dependent signaling by the platelet collagen receptor glycoprotein VI. J Bioi Chern. 2003; 278:15441-8.

Luzak B, Golanski J, Rozalski M, Bonclerand MA, Watala C. Inhibition of collagen-induced platelet reactivity by DGEA peptide. Acta Biochim Pol. 2003; 50:1119-28.

Maakaroun A, Regina S, Delahousse B, Saudeau D, Gruel Y. Ischaemic strokes and homozygosity for the [ alpha]2 807T allele of the platelet collagen receptor in young monozygotic twins. Blood Coagul Fibrinolysis. 2003; 14: 83-5.

Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vase Bioi. 2004; 24:1015-22.

Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vase Bioi. 2007 ;27:1687-93.

Maclean AA, Pena CS, Katzen BT. Bivalirudin in peripheral interventions. Tech Vase lnterv Radio!. 2006 ;9:80-3.

Mangin P, Yuan Y, Goncalves I, Eckly A, Freund M, Cazenave JP, Gachet C, Jackson SP, Lanza F. Signalipg role for phospholipase C gamma 2 in platelet glycoprotein Ib alpha calcium flux and cytoskeletal reorganization. Involvement of a pathway distinct from FeR gamma chain and Fe gamma RIIA. J Bioi Chern. 2003; 278:32880-91.

Mangin P, Yap CL, Nonne C, Sturgeon SA, Goncalves I, Yuan Y, Schoenwaelder SM, Wright CE, Lanza F, Jackson SP. Thrombin overcomes the thrombosis defect associated with platelet GPVI!FcRgamma deficiency. Blood. 2006; 107:4346-53.

137

References

Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vase Bioi. 2003; 23:17-25.

Marcus AJ, Safier LB, Hajjar KA, Ullman HL, Islam N, Broekman MJ, Eiroa AM. Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells. J Clin Invest. 1991; 88:1690-6.

Marjanovic JA, Li Z, Stojanovic A, Du X. Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation. J Bioi Chern. 2005; 280:37430-8.

Markwardt F. The development of hirudin as an anti thrombotic drug. Thromb Res. 1994; 74:1-23.

Martina V, Bruno GA, Trucco F, Zumpano E, Tagliabue M, Di Bisceglie C, Pescarmona G. Platelet eNOS activity is reduced in patients with IDDM and NIDDM. Thromb Haemost. 1998;79:520-2.

Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002; 196:887-96.

Massberg S, Gawaz M, Gruner S, Schulte V, Konrad I, Zohlnhofer D, Heinzmann U, Nieswandt B. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Me d. 2003; 197:41-9.

Matsushita K, Morrell CN, Cambien B, Yang SX, Yamakuchi M, Bao C, Hara MR, Quick RA, Cao W, O'Rourke B, Lowenstein JM, Pevsner J, Wagner DD, Lowenstein CJ. Nitric oxide regulates exocytosis by S-nitrosylation of N­ethylmaleimide-sensitive factor. Cell. 2003; 115:139-50.

Maurice P, Pires V, Amant C, Kauskot A, Da Nascimento S, Sonnet P, Rochette J, Legrand C, Fauvel-Lafeve F, Bonnefoy A. Antithrombotic effect of the type III collagen-related octapeptide (KOGEOGPK) in the mouse. Vascui Pharmacal. 2006; 44: 42-9.

McDonald LJ, Murad F. Nitric oxide and cyclic GMP signaling. Proc Soc Exp Bioi Med. 1996; 211:1-6.

Mcintyre TM, Zimmerman GA, Satoh K, Prescott SM. Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate. J Clin Invest. 1985; 76:271-80.

McNicol A, Gerrard JM. Platelet morphology, aggregation and secretion. In: Advances in molecular and cell biology. Greenwich: JAI Press Inc.; 1997. p. 1-29.

138

References

McNicol A, Israels SJ. Platelets and anti-platelet therapy. J Pharmacal Sci. 2003; 93:381-96.

Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions ofHDL. Circ Res. 2006; 98:1352-64.

Miura Y, Takahashi T, Jung SM, Moroi M. Analysis ofthe interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen. J Bioi Chern. 2002; 277:46197-204.

Mohammad SF; Woodward SC. Characterization of a potent inhibitor of platelet aggregation and release reaction isolated from allium sativum (garlic). Thromb Res. 1986;44:793-806.

Mohri H, Ohkubo T. The role of the RGD peptides and the gamma chain peptide of fibrinogen on fibrinogen binding to activated platelets. Peptides. 1993; 14:353-7.

Molina V, Carbajal D, Arruzazabala L, Mas R. Effect of D-003 on intravascular platelet aggregation induced with collagen in rats. J Med Food 2005; 8:232-6.

Momi S, Emerson M, Paul W, Leone M, Mezzasoma AM, Del Soldato P, Page CP, Gresele P. Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Eur J Pharmacal. 2000; 397:177-85.

Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. Thromb Res. 2004; 114:.221-33.

Morrissey JH. Tissue factor: An enzyme cofactor and a true receptor. Thromb Haemost. 2001; 86:66-74.

Moshfegh K, Wuillemin WA, Redondo M, Lammle B,Beer JH, Liechti-Gallati S, Meyer BJ. Association of two silent polymorphisms of platelet glycoprotein Iallla receptor with risk of myocardial infarction: a case-control study. Lancet. 1999; 353: 351-4.

Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109:3161-72.

Mousa SA, Bozarth JM, Seiffert D, Feuerstein GZ. Using thrombelastography to determine the efficacy of the platelet glycoprotein lib/lila antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans. Blood Coagul Fibrinolysis. 2005; 16:165-71.

Mousa SA, Ahmad S. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia. Am J Hematol. 2007; 82:276-82.

139

References

Munnix IC, Strehl A, Kuijpers MJ, Auger JM, van der Meijden PE, van Zandvoort MA, oude Egbrink MG, Nieswandt B, Heemskerk JW. The glycoprotein VI-phospholipase Cgamma2 signaling pathway controls thrombus formation induced by collagen and tissue factor in vitro and in vivo. Arterioscler Thromb Vase Bioi. 2005; 25:2673-8.

Murugappan S, Tuluc F, Dorsam RT, Shankar H, Kunapuli SP. Differential role of protein kinase C delta isoform in agonist-induced dense granule secretion in human platelets. J Bioi Chern. 2004; 279:2360-7.

Myers DD Jr, Henke PK, Bedard PW, Wrobleski SK, Kaila N, Shaw G, Meier TR, Hawley AE, Schaub RG, Wakefield TW. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis modelofvenous thrombosis. J Vase Surg. 2006; 44:625-32.

Nabata H, Uchino M, Okazaki A, Yamazaki T, Sakai K. Antithrombotic and ulcerogenic effects of fenflumizole, a new anti-inflammatory imidazole derivative, in rats. Jpn J Pharmacal. 1987;44:93-6.

Nadal F, Levy-Toledano S, Grelac F, Caen JP, Rosa JP, Bryckaert M. Negative regulation of . mitogen-activated protein kinase activation by integrin alphaiibbeta3 in platelets. J Bioi Chern. 1997; 272:22381-4.

Nakagawa K, Hirai T, Sakurai K, Ohara K, Nozawa T, Inoue H. Thoracic aortic plaque enhances hypercoagulability in patients with nonrheumatic atrial fibrillation. Circ J 2007; 71:52-6.

Napoli C, Cirino G, Del Soldato P, Sorrentino R, Sica V, Condorelli M, Pinto A, Ignarro LJ. Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc Nati A cad Sci US A. 2001 ;98 :2860-4.

Napoli C, Aldini G, Wallace JL, de Nigris F, Maffei R, Abete P, Bonaduce D, Condorelli G, Rengo F, Sica V, D'Armiento FP, Mignogna C, de Rosa G, Condorelli M, Lerman LO, Ignarro LJ. Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc Nati Acad Sci U S A. 2002a;99: 1689-94.

Napoli C, Ackah E, De Nigris F, Del Soldato P, D'Armiento FP, Crimi E, Condorelli M, Sessa WC. Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice. Proc Nati A cad Sci US A. 2002b; 99:12467-70.

Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid · receptor function. J Clin Invest. 2001; 108:25-30.

140

References

Neumann FJ, GawazM, Dickfeld T, Wehinger A, Walter H, Blasini R, Schomig A. Antiplatelet effect of ticlopidine after coronary stenting. J Am Coil Cardia!. 1997; 29:1515-9.

Newton AC. Protein kinase C: structure, function, and regulation. J Biol Chern. 1995; 270:28495-8.

Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000; 106:385-92.

Nieswandt B, Bergmeier W, Schulte V, Rackebrandt K, Gessner JE, Zirngibl H. Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FeR y-chain. J Biol Chern. 2000; 275: 23998-4002.

Nieswandt B, Bergmeier W, Eckly A, Schulte V, Ohlmann P, Cazenave JP, Zirngibl H, Offermanns S, Gachet C. Evidence for cross-talk between glycoprot~in VI and Gi-coupled receptors during collagen-induced platelet aggregatidn. Blood. 2001a; 97:3829-35.

Nieswandt B, Schulte V, Bergm.eier W, Mokhtari-Nejad R, Rackebrandt K, Cazenave JP, Ohlmann P, Gachet C, Zirngibl H. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med. 2001b; 193:459-69.

Nieswandt B, Brakebusch C, Bergmeier W, Schulte V, Bouvard D, Mokhtari­Nejad R, Lindhout T, Heemskerk JW, Zirngibl H, Fassler R. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 2001c;20:2120-30.

Nieswandt B, Watson SP. Platelet-collagen interaction: IS GPVI the central receptor? Blood. 2003; 102:449-61.

Nieswandt B, Aktas B, Moers A, Sachs UJH. Platelets in atherothrombosis: lessons from mouse models. J Thromb Haemost. 2005; 3: 1725-36.

Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature. 1985; 318:470-2.

Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature. 1984; 308:693-8.

Nityanand S, Pande I, Bajpai VK, Singh L, Chandra M, Singh BN. Platelets in essential hypertension. Thromb Res. 1993; 72:447-54.

141

References

Nomura S. Function and clinical significance of platelet derived microparticles. Jnt J Hematol. 2001; 74:397-404.

Nonne C, Lenain N, Hechler B, Mangin P, Cazenave JP, Gachet C, Lanza F. Importance of platelet phospholipase Cgamma2 signaling in arterial thrombosis as a function oflesion severity.Arterioscler Thromb Vase Bioi. 2005;25: 1293-8.

Obergfell A, Judd BA, del Pozo MA, Schwartz MA, Koretzky GA, Shattil SJ. The molecular adapter SLP-76 relays signals from platelet integrin alphallbbeta3 to the actin cytoskeleton. J Bioi Cheni. 2001; 276:5916-23.

Obergfell A, Eto K, Mocsai A, Buensuceso C, Moores SL, Brugge JS, Lowell CA, Shattil SJ. Coordinate interactions of Csk, Src, and Syk kinases with [ alpha]Ilb[beta]3 initiate integrin signaling to the cytoskeleton. J Cell Bioi. 2002;157:265-75.

Ogihara Y, Muramatsu S, Kaneda Y, Iijima T, Shibutani T, and Shibano T. Pharmacological Profile of DZ-697b, a Novel Anti-Platelet Agent -Selective Inhibitor of vWF- and Collagen-Induced Platelet Aggregation. Blood (ASH Annual Meeting Abstracts) 2005; I 06: 1875.

Oury C, Kuijpers MJ, Toth-Zsamboki E, Bonnefoy A, Danloy S, Vreys I, Feijge MA, DeVos R, Vermylen J, Heemskerk JW, Hoylaerts MF. Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood. 2003; 101:3969-76.

Packham MA. Role of platelets in thrombosis and hemostasis. Can J Physiol Pharmacal. 1994;72:278-84.

Papadopoulos S, Flynn JD, Lewis DA. Fondaparinux as a treatment option for heparin-induced thrombocytopenia. Pharmacotherapy. 2007 ;27 :921-6.

Parise LV. Integrin alpha( lib )beta(3) signaling in platelet adhesion and aggregation. Curr Opin Cell Bioi. I999; 11: 597-60 I.

Parker PJ; Murray-Rust J. PKC at a glance. J Cell Sci. 2004; 117:131-2.

Pasquet JM, Gross B, Quek L, Asazuma N, Zhang W, Sommers CL, Schweighoffer E, Tybulewicz V, Judd B, Jong Ran Lee, Koretzky G, Love PE, Samelson LE, Watson SP. LA T is required for tyrosine phosphorylation of phospholipase Cy2 and platelet activation by the collagen receptor GPVI. Mol Cell Bioi. 1999; 19: 8326-34.

Pearce AC, Senis YA, Billadeau DD, Turner M, Watson SP, Vigorito E. Vav1 and vav3 have critical but redundant roles in mediating platelet activation by collagen. J Bioi Chern. 2004; 279:53955-62.

142

References

Pea:rs CJ, Parker PJ. Domain interactions in protein kinase C. J Cell Sci. 1991; 100:683-6.

Pearson JD. Endothelial cell function and thrombosis. Baillieres Best Pract Res Clin Haematol. ·1999; 12:329-41

Pellizzon GG, Dixon SR, Stone GW, Cox DA, Mattos L, Boura JA, Grines LL, Addala S, O'Neill WW, Grines CL. Stent PAMI Investigators. Relation of admission white blood cell count to long-term outcomes after primary coronary angioplasty for acute myocardial infarction (The Stent P AMI Trial). Am J Cardiol. 2003; 91:729-31.

Penz S, Reininger AJ, Brandl R, Goyal P, Rabie. T, Bernlochner I, Rother E, Goetz C, Engelmann B, Smethurst P A, Ouwehand WH, Farndale R, Nieswandt B, Siess W. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J 2005; 19:898-909.

Persist Investigators. A novel long-acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation [abstract]. Blood. 2002; 100:301.

Perutelli P, Mori PG. Biochemical and molecular basis of Glanzmann's thrombasthenia. Haematologica. 1992;77:421-6.

Peter K, Schwarz M, Ylanne J, Kohler B, Moser M, Nordt T, Salbach P, Kubler W, Bode C. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein lib/lila (alphallbbeta3) inhibitors. Blood. 1998 ;92:3240-9.

Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein lib-lila complex. Blood. 1988; 71: 831-43.

Phillips DR, Nannizzi-Alaimo L, Prasad KS. Beta3 tyrosine phosphorylation in alphallbbeta3 (platelet membrane GP lib-lila) outside-in integrin signaling. Thromb Haemost. 2001; 86: 246-58.

Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Nat! Acad Sci US A. 2000;97:6930-2.

Pinsky DJ, Broekman MJ, Peschon JJ, Stocking KL, Fujita T, Ramasamy R, Connolly ES Jr, Huang J, Kiss S, Zhang Y, Choudhri TF, McTaggart RA, Liao H, Drosopoulos JH, Price VL, Marcus AJ, Maliszewski CR. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest. 2002; 109: 1031- 40.

Polanowska-Grabowska R, Geanacopoulos M, Gear AR. Platelet adhesion to collagen via the alpha 2 beta 1 integrin under arterial flow conditions causes rapid tyrosine phosphorylation of pp 125F AK. Biochem J 1993; 296:543-7.

143

References

Polanowska-Grabowska R, Gibbins JM, Gear AR. Platelet adhesion to collagen and collagen-related peptide under flow: roles of the a2P1 integrin, GPVI, and Src tyrosine kinases. Arterioscler Thromb Vase Bioi. 2003; 23: 1934-40.

Polgar J, Clemetson JM, Kehrel BE, Wiedemann M, Magnenat EM, Wells TN, Clemetson KJ. Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. J Bioi Chern. 1997; 272:13576-83.

Pravenec M, Kunes J, Zicha J, Kren V, Klir P. Platelet aggregation in spontaneous hypertension: genetic determination and correlation analysis. J Hypertens. 1992; 10:1453-6.

Pressman BC. Properties of ionophores with broad range cation selectivity. Fed Proc. 1973; 32:1698-703.

Quek LS, Pasquet JM, Hers I, Cornall R, Knight G, Barnes M, Hibbs ML, Dunn AR, Lowell CA, Watson SP. Fyn and Lyn phosphorylate the Fe receptor y chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway. Blood. 2000; 96:4246-53.

Quinton TM, Kim S, Dangelmaier C, Dorsam RT, Jin J, Daniel JL, Kunapuli SP. Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation. Biochem J 2002a; 368:535-43.

Quinton TM, Ozdener F, Dangelmaier C, Daniel JL, Kunapuli SP. Glycoprotein VI-mediated platelet fibrinogen receptor activation occurs through calcium­sensitive and PKC-sensitive pathways without a requirement for secreted ADP. Blood. 2002b; 99: 3228-34.

Raghavan SAV, Dikshit M. Recent advances in the status and targets of antithrombotic agents. Drugs Fut. 2002; 27:669-83.

RaghavanSAV, Dikshit M. L-citrulline mediated relaxation in the control and lipopolysaccharide-treated rat aortic rings. Eur J Pharmacal. 2001; 431:61-9.

Rahman K, Billington D. Dietary supplementation with aged garlic extract inhibits ADP-in.duced platelet aggregation in humans. J Nutr. 2000; 130:2662-5.

Razmara M, HuH, Masquelier M, LiN. Glycoprotein lib/lila blockade inhibits platelet aminophospholipid exposure by potentiating translocase and attenuating scramblase activity. Cell Mol Life Sci. 2007;64:999-1008.

Rebello SS, Driscoll EM, Lucchesi BR. TP-9201, a glycoprotein lib/Ilia platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke. 1997; 28 :1789-96.

144

References

Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets. 2001; 12:261-73.

Rezaie AR. Kinetics of factor Xa inhibition by recombinant tick anticoagulant peptide: both active site and exosite interactions are required for a slow- and tight­binding inhibition mechanism. Biochemistry. 2004; 43:3368-75.

Rosamond WD, Chambless LE, Folsom AR, Cooper LS, Conwfll DE, Clegg L, Wang CH, Heiss G. Trends in the incidence of myocardial infarction and m mortality due to coronary heart disease, 1987 to 1994. N Eng! J Med. 1998; 339:861-7.

Rosove MH. Platelet glycoprotein lib/Ilia inhibitors. Best Pract Res Clin Haeinatol. 2004; 17:65-76.

Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138:S419-20.

Rozalski M, . Bonder M, Luzak B, Watala C. Genetic factors underlying differential blood platelet sensitivity to inhibitors. Pharmacal Rep. 2005; 57:1-13.

Sakai K, Yamazaki T, Nakamura Y, Sugimoto T. Protective effects of the antianginal agent nicorandil on arachidonate-induced sudden death in rats: comparison with several antianginal agents and cyclooxygenase inhibitors. Jpn J Pharmacal. 198.5;37:124-8.

Saklatvala J, Rawlinson L, Waller RJ, Sarsfield S, Lee JC, Morton LF, Barnes MJ, Famdale RW. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J Bioi Chem. 1996; 271:6586-9.

Saller F, Bumier L, Schapira M, Angelillo-Scherrer A. Role of the growth arrest­specific gene 6 (gas6) product in thrombus stabilization. Blood Cells Mol Dis. 2006; 36:373-8.

Samaha FF, Hibbard C, Sacks J, Chen H, Varello MA, George T, Kahn ML. Density of platelet collagen receptors glycoprotein VI and a 2p1 and prior myocardial infarction in human subjects, a pilot study. Med Sci Manit. 2005; 11: CR224-229.

Sambrano GR, ,Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001;413:74-8.

Sankaranarayanan A, Narender T, Kumar S, Dikshit M. Allium sativum constituents: effect on free radical generation from rat neutrophils. Cell Mol Bioi (Noisy-le-grand). 2007; 53:63-7.

145

References

Sargeant P, Sage SO. Calcium signalling in platelets and other nonexcitable cells. Pharmacal Ther. 1994;64:395-443.

Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Gohring W, Ullrich A, Timpl R, Hohenester E. Structural basis for Gas6-Axl signalling. EMBO J 2006; 25:80-7.

Sase K, Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci. 1995; 57:2049-55.

Schaefer WM, Koch KC, Nowak B, Noth J, Buell U, Weiss PH. Dipyridamole/aspirin combination in secondary stroke prevention: effects on absolute myocardial blood flow and coronary vascular resistance. /nt J Clin Pharmacal Ther. 2006;44:319-25.

Schlossmann J, Feil R, Hofmann F. Signaling through NO and cGMP-dependent protein kinases.1nn Med. 2003; 35:21-7.

Schmid-Schonbein GW, Sung K-LP, Tozeren H. Influence of physicochemical factors on rheology ofhuman neutrophils. Biophys J 1982; 39:101-6.

Schonbeck U, Mach F, Sukhova GK, Herman M, Graber P, Kehry MR, Libby P. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol. 2000; 156:7-14.

Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266-8

Schulte V, Reusch HP, Pozgajova M, Varga-Szabo D, Gachet C, Nieswandt B. Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice. Arterioscler Thromb Vase Bioi. 2006; 26:1640-7.

Serebruany VL, Midei MG, Meilman H, Malinin AI, Lowry DR. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. Postgrad Med J 2006; 82:404-10.

Shattil SJ, Ginsberg MH. Integrin signaling in vascular biology. J Clin Invest. 1997; 100:S91-5.

Shattil SJ; Kashiwagi H, Pam pori N. Integrin signaling: the platelet paradigm. Blood. 1998; 91: 2645-57.

Shaughnessy SG, YoungE, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from the fetal rat calvaria. Blood. 1995; 86:1368-73.

Shibutani T, Iijima T, Kaneda Y, Muramatsu S, Ogihara Y, and Shibano T. Anti­Thrombotic Action of DZ-697b, a Novel Anti-Platelet Agent, on Photochemically

146

References

Induced Thrombosis with Lower Bleeding Risk in Guinea Pigs. Blood (ASH Annual Meeting Abstracts) 2005; 106: 1870.

Siegel-Axel DI, Gawaz M. Platelets and endothelial cells. Semin Thromb Hemost. 2007; 33:128-35.

Siess W, La~etina EG. Ca2+ mobilization primes protein kinase C in human

platelets. Ca + and phorbol esters stimulate platelet aggregation and secretion synergistically through protein kinase C. Biochem J 1988; 255:309-18.

Siess W. Molecular mechanisms of platelet activation. Physiol Rev. 1989; 69: 58-178.

Siljander P, Famdale RW, Feijge MA, Comfurius P, Kos S, Bevers EM, Heemskerk JW. Platelet adhesion enhances the glycoprotein VI-dependent procoagulant response: Involvement ofp38 MAP kinase and calpain. Arterioscler Thromb Vase Biol. 2001; 21:618-27.

Siljander PR, Munnix IC, Smethurst PA, Deckmyn H, Lindhout T, Ouwehand WH, Famdale RW, Heemskerk JW. Platelet receptor interplay regulates collagen­induced thrombus formation in flowing human blood. Blood. 2004; 103: 1333-41.

Simon DI, Chen Z, Seifert P, Edelman ER, Ballantyne CM, Rogers C. Decreased neointimal formation in Mac-1(-/-) mice reveals a role for inflammation m vascular repair after angioplasty. J Clin Invest. 2000; 105:293-300.

Singh S, Majumdar DK. Evaluation of antiinflammatory activity of fatty acids of Ocimum sanctum fix,ed oil. Ind J Exp Biol. 1997; 35: 380-3.

Singh S, Rehan HMS, Majumdar DK. Effect of Ocimum sanctum fixed oil on blood pressure, blood clotting time and pentobarbitone-induced sleeping time. J Ethnopharmacol. 2001; 78; 139-43.

Slupsky JR, Kalbas M, Willuweit A, Henn V, Kroczek RA, Muller-Berghaus G. Activated platelets induce tissue factor expression on human umbilical vem endothelial cells by ligation of CD40. Thromb Haemost. 1998; 80:1008-14.

Smethurst PA, Joutsi-Korhonen L, O'Connor MN, Wilson E, Jennings NS, Garner SF, Zhang Y, Knight CG, Daffom TR, Buckle A, IJsseldijk MJW, de Groot PG, Watkins NA, Farndale RW, Ouwehand WH. Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood. 2004; 103: 903-11.

Soulet C, Gendreau S, Missy K, Benard V, Plantavid M, Payrastre B. Characterisation of Rae activation in thrombin- and collagen-stimulated human blood platelets. FEES Lett. 2001; 507:253-8.

147

References

Spalding A, Vaitkevicius H, Dill S, MacKenzie S, Schmaier A, Lockette W. Mechanism of epinephrine-induced platelet aggregation. Hypertension. 1998; 31:603-7.

Srivastava KC. Aqueous extracts of onion, garlic and ginger inhibit platelet aggregation and alter arachidonic acid metabolism. Biomed Biochim Acta. 1984;43 :S335-46.

Srivastava KC. Evidence for the mechanism by which garlic inhibits platelet aggregation. Prostaglandins Leukot Med. 1986a; 22:313-21.

Stafford MJ, Watson SP, Pears CJ. PKD: a new protein kinase C-dependent pathway in platelets. Blood. 2003; 101:1392-9.

Steiner M, Lin RS. Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract. J Cardiovasc Pharmacal. 1998; 31:904-8.

Stilz HU, Guba W, Jablonka B, Just M, Klingler 0, Konig W, Wehner V, Zoller G. Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold. J Med Chern. 2001; 44:1158-76.

Stojanovic A, Marjanovic JA, Brovkovych VM, Peng X, Hay N, Skidgel RA, Du X. A phosphoinositide 3-kinase-AKT -nitric oxide-cGMP signaling pathway in stimulating platelet secretion and aggregation. J Bioi Chern. 2006; 281:16333-9.

Sumitra M, Manikandan P, Dilly AK, Arutselvan N, Balakrishna K, Manohar BM, Puvanakrishnan R. Experimental myocardial necrosis in rats: Role of arjunolic acid on platelet aggregation, coagulation and antioxidant status. Mol Cell Biochem. 2001; 224; 135-42.

Suzuki-Inoue K~ Yatomi Y, Asazuma N, Kainoh M, Tanaka T, Satoh K, Ozaki Y. Rae, a small guanosine triphosphate-binding protein, and p21-activated kinase are activated during platelet spreading on collagen-coated surfaces: roles of integrin alpha(2)beta(l). Blood. 2001; 98:3708-16.

Suzuki-Inoue K, Tulasne D, Shen Y, Bori-Sanz T, Inoue 0, Jung S.M, Moroi M, Andrews RK, Berndt MC, Watson SP. Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling. J Bioi Chern. 2002; 277: 21561-6.

Suzuki-Inoue K, Fuller GL, Garcia A, Eble JA, Pohlmann S, Inoue 0, Gartner TK, Hughan SC, Pearce AC, Laing GD, Theakston RD, Schweighoffer E, Zitzmann N, Morita T, Tybulewicz VL, Ozaki Y, Watson SP. A novel Syk­dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2006; 107:542-9.

148

References

Teng CM, LinCH, Lin CN, Chung MI, Huang TF. Frangulin B, an antagonist of collagen-induced platelet aggregation and adhesion, isolated from Rhamnus formosana. Thromb Haemost. 1993; 70:1014-8.

Thebault JJ, Kieffer G, Lowe GD, Nimmo WS, Cariou R. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost. 1999;25 Suppl2:9-14.

Thomas DW, Mannon RB, Mannon PJ, Latour A, Oliver JA, Hoffman M, Smithies 0, Koller BH, Coffman TM. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2• J Clin Invest. 1998; 102:1994-2001.

Toothill VJ, Van Mourik JA, Niewenhuis HK, Metzelaar MJ, Pearson JD. Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin­stimulated endothelial cells. J Immunol. 1990; 145:283-91.

Topol EJ. GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein lib/Ilia inhibition: the GUSTO V randomised trial. Lancet. 2001; 357:1905-14.

Troconiz IF, Tillmann C, Liesenfeld KH, Schafer HG, Stangier J. Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1 048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacal. 2007; 47:371-82.

Tschoepe D, Driesch E, Schwippert B, Nieuwenhuis HK, Gries FA. Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia. Diabetes. 1995; 44:890-4.

Tschoepe D, Roe sen P, Schwippert B, Gries FA. Platelets in diabetes: the role in the hemostatic. regulation in atherosclerosis. Semin Thromb He most. 1993; 19:122-8.

Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fe receptor c­chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Bioi Chem.1997; 272: 23528-31.

Tsukuda M, Asaoka Y, Sekiguchi K, Kikkawa U, Nishizuka Y. Properties of protein kinase C subspecies in human platelets. Biochem Biophys Res Commun. 1988; 155:1387-95.

Turitto VT, Baumgartner HR. Platelet interaction with subendothelium in a perfusion system: Physical role of red blood cells. Microvasc Res. 1975; 9:335-44.

149

References

Turitto VT, Weiss HJ: Red blood cells: Their dual role in thrombus formation. Science. 1980; 207:541-3.

Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007; 109:2285-92.

Vaidyula VR, Rao AK. Role of Galphaq and phospholipase C-beta2 in human platelets activation by thrombin receptors PARI and PAR4: studies in human platelets deficient in Galphaq and phospholipase C-beta2. Br J Haematol. 2003;121 :491-6.

Vallar L, Melchior C, Plancon S, Drobecq H, Lippens G, Regnault V, Kieffer N. Divalent cations differentially regulate integrin alphaiib cytoplasmic tail binding to beta3 and to calcium- and integrin-binding protein. J Biol Chem. 1999; 274:17257-66.

van den Eijnden MM, Steenhauer SI, Reitsma PH, Bertina RM. Tissue factor expression during monocyte-macrophage differentiation. Thromb Haemost. 1997;77: 1129-36.

Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003; 110:255-8.

Vanhoorelbeke K, Ulrichts H, Schoolmeester A, Deckmyn H. Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs. Curr Drug Targets Cardiovasc Haematol J?isord 2003; 3:125-40.

Varenhorst E, Svensson M, Hjertberg H, Malmqvist E. Antithrombin III concentration, thrombosis, and treatment with luteinising hormone releasing. hormone agonist in prostatic carcinoma. Br Med J (Clin Res Ed). 1986; 292:935-6

Verstraete M. Heparin and thrombosis: a seventy year long story. Haemostasis. 1990; 20 Suppl 1 :4-1.

Vial C, Pitt SJ, Roberts J, Rolf MG, Mahaut-Smith MP, Evans RJ. Lack of evidence for functional ADP-activated human P2X1 receptors supports a role for ATP during hemostasis and thrombosis. Blood 2003; 102:3646-51.

Vidal C, Geny B, Melle J, Jandrot-Perrus M, Fontenay-Roupie M. Cdc42/Rac1-dependent activation of the p21-activated kinase (P AK) regulates human platelet lamellipodia spreading: implication of the cmiical-actin binding protein cortactin. Blood 2002; 100:4462-9.

Vretenbrant K, Ramstrom S, Bjerke M, Lindahl TL. Platelet activation via P AR4 is involved in the initiation of thrombin generation and in clot elasticity development. Thromb Haemost. 2007; 97:417-24.

150

References

Wadhawan V, Karim ZA, Mukhopadhyay S, Gupta R, Dikshit M, Dash D. Platelet storage under in vitro condition is associated with calcium-dependent apoptosis-like lesions and novel reorganization in platelet cytoskeleton. Arch Biochem Biophys. 2004; 422:183-90.

Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPilb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996; 88: 907-14.

Walker TR, Watson SP. Synergy between Ca2+ and protein kinase Cis the major

factor in determining the level of secretion from human platelets. Biochem J 1993; 289: 277-82.

Wang YX, Vincelette J, da Cunha V, Martin-McNulty B, Mallari C, Fitch RM, Alexander S, Islam I, Buckman BO, Yuan S, Post JM, Subramanyam B, Vergona R, Sullivan ME, Dole WP, Morser J, Bryant J. A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thromb Haemost. 2007; 97:847-55.

Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Nat! Acad Sci U S A. 2000; 97:2803-8.

Watanabe N, Nakajima H, Suzuki H, Oda A, Matsubara Y, Moroi M, Terauchi Y, Kadowaki T, Suzuki H, Koyasu S, Ikeda Y, Handa M. Functional phenotype of phosphoinositide 3-kinase p85a-null platelets characterized by an impaired response to GP VI stimulation. Blood. 2003; 102: 541-8.

Watson S, Berlanga 0, Best D, Frampton J. Update on collagen receptor interactions in platelets: is the two-state model still valid? Platelets. 2000; 11 :252-8.

Weiss EJ, Hamilton JR, Lease KE, Coughlin SR. Protection against thrombosis in mice lacking PAR3. Blood. 2002;100:3240-4.

Weissman G, Smolen JE, Korchak HM. Release of inflammatory mediators from stimulated neutrophils. New Eng/ J Med.1980; 303:27-34.

Weitz JI, Hirsh J. New anticoagulant drugs. Chest. 2001; 119:95S-1 07S.

Wonerow P, Pearce AC, Vaux DJ, Watson SP. A critical role for phospholipase Cgamma2 in alphallbbeta3-mediated platelet spreading. J Bioi Chern. 2003;278:37520-9.

Xiao Z, Goldsmith HL, Mcintosh FA, Shankaran H, Neelamegham S. Biomechanics of P-selectin PSGL-1 bonds: shear threshold and integrin­independent cell adhesion. Biophys J 2006;90:2221-34.

151

References

Xie QW, Cho HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TD, Ding A, Troso T, Nathan C. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science. 1992; 256:225-8.

Xu G, Ulrichts H, Vauterin S, De ,Meyer SF, Deckmyn H, Teng M, Niu L. How does agkicetin-C bind on platelet glycoprotein Iba and achieve its platelet effects? Toxicon. '2005; 45:561-70.

Yacoub D, Theoret JF, Villeneuve L, Abou-Saleh H, Mourad W, Allen BG, Merhi Y. Essential role of protein kinase C delta in platelet signaling, alpha lib beta 3 activation, and thromboxane A2 release. J Bioi Chern. 2006; 281:30024-35.

Yamamoto M, Nakagaki T, Kisiel W. Tissue factor-dependent autoactivation of human blood coagulation factor VII. J Bioi Chern. 1992; 267:19089-94.

Yang SA, Carpenter CL, Abrams CS. Rho and Rho-kinase mediate thrombin­induced phosphatidylinositol 4-phosphate 5-kinase trafficking in platelets. J Bioi Chern. 2004; 279:42331-6.

Yeh RW, Jang IK. Argatroban: update. Am Heart J 2006; 151:1131-8.

Yoshida M, Sato Y, Shimura T, Ohkubo S, Honma S, Tanaka T, Kurimoto T, Nakahata N. Distinct effects ofz-335, a new thromboxane A2 receptor antagonist, on rabbit platelets and aortic smooth muscle. Pharmacology. 2007; 79:50-6.

Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng! J Med. 2001; 345:494-502.

Zakir RM, Hoffman W, Bhatt BA, Spillert CR. A functional clotting assay to monitor the hirudin dosage. Blood Coagui Fibrinolysis. 2007; 18:119-23.

Zhao Y, Wang Y, Zhu J. Correlation between the polymorphism of glycoprotein Ia gene and acute coronary syndrome. Chin Med Sci J · 2004; 19: 13-8.

Zheng YM, Liu C, Chen H, Locke D, Ryan JC, Kahn ML. Expression of the platelet receptor GPVI confers signaling via the Fe receptor gamma -chain in response to the.snake venom convulxin but not to collagen. J Biol Chern. 2001; 276: 12999-3006.

Zhu J, Cole F, Woo-Rasberry V, Fang XR, Chiang TM. Type I and type III collagen-platelet interaction: Inhibition by type specific receptor peptides. Thromb Res. 2007; 119:111-9.

152

APPENDIX

PUBLICATIONS

Abstracts:

Surin WR, Batra S, Roy AK, Patra A, Bhaduri A P, Raghavan SA V, Kapoor K and Dikshit M. Antithrombotic activity of a 3, 5-disubstituted isoxazole compound in various models ofthrombosis. Ind. J. Pharmacol2003.

Surin WR and Dikshit M. Effect o/antiplatelet and anti-coagulant drugs on ferric chloride induced thrombosis in rats. I.nd. J. Pharmacol2006; 38: S47.

Research Articles Published:

Batra S, Roy AK, Patra A, Bhaduri AP, Surin WR, Raghavan SA, Sharma P, Kapoor K,Dikshit M. Baylis-Hillman reaction assisted parallel synthesis of 3,5-disubstitutedisoxazoles and their in vivo bioevaluation as antithrombotic agents. Bioorg Med Chem. 2004; 12:2059-77.

Surin WR, Barthwal MK, Dikshit M. Collagen receptors, signaling and consequences of their inhibitions on platelet functions: An emerging approach to prevent intra-vascular thrombosis. Thrombosis Research (Revised manuscript submitted)

Patents Filed:

PATENT APPL. NO. 01258DELNP2005 FILING DATE: 31-03-2005 PATENT APPL. NO. PCT/INOS/00417 FILING DATE: 27-12-2004 2-Alkyl aryl sufonyl-1 ,2,3,4, tetrahydro-9H pyrido [3,4,6] indole 3-carboxylic acid esters and amides as anti-thrombotic agent.

Chapter contributed:

W.R. Surin and Madhu Dikshit. Prevention of Intravascular Thrombosis: Research on Indian Herbs and Spices. Herbal Drug Research: A Twenty First Century Perspective (Publisher: Jaypee Brothers Medical Publishers (P) Ltd.)

153